On 16 January 2014, orphan designation (EU/3/13/1218) was granted by the European Commission to Proteon Therapeutics Limited, United Kingdom, for recombinant human type I pancreatic elastase for the prevention of arteriovenous access dysfunction in haemodialysis patients.
This medicine is now known as vonapanitase.
The sponsorship was transferred to Pharma Gateway AB Sweden, in April 2019.
Recombinant human type I pancreatic elastase for the prevention of arteriovenous access dysfunction in haemodialysis patients (vonapanitase)
|Disease / condition||
Prevention of arteriovenous access dysfunction in haemodialysis patients
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;